Survival analysis by gender and risk group for HIV in Edinburgh. NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Survival analysis by gender and risk group for HIV in Edinburgh.

Int Conf AIDS. 1992 Jul 19-24;8(1):Mo18 (abstract no. MoC 0066). Unique Identifier : AIDSLINE ICA8/92400023
Brettle RP; Richardson AM; Burns SM; Fielding K; Leen CL; City Hospital, Edinburgh, UK.

Abstract: OBJECTIVE: Survival analysis for HIV infected individuals. METHOD: Between 1984-91 306/603 HIV infected patients were seen with a seroconversion date (stored sera up to 2 years apart). Survival was analysed (Kaplan-Meier method and log rank test) from seroconversion to AIDS, to CD4 200 (the date determined by the first of two CD4 counts less than 200 cells/cumm) and to death from any cause. RESULTS: The cumulative probability of survival from seroconversion is shown below for all, drug users (DUs) and non drug users (NDUs). TABULAR DATA, SEE ABSTRACT VOLUME. No significant differences for risk group or gender except for seroconversion to AIDS where drug users did better. The median survival of 119 patients with AIDS was 20.75 mths (14% survival at 3 years) with no differences for risk group and gender. The median survival for 210 patients from CD4 200 to death was 38.2 mths (24% survival at 5 yrs) with a significant difference for DUs vs NDUs (46.07 vs 29.51, p less than 0.05). CONCLUSIONS: With a uniform medical care, survival to a variety of endpoints, is not adversely affected by gender or drug use.
Keywords: Acquired Immunodeficiency Syndrome/EPIDEMIOLOGY Comorbidity Comparative Study CD4-Positive T-Lymphocytes Female Human HIV Infections/*MORTALITY HIV Seropositivity/EPIDEMIOLOGY Leukocyte Count Life Tables Male Probability Risk Factors Scotland/EPIDEMIOLOGY Sex Factors Substance Abuse, Intravenous/EPIDEMIOLOGY Survival Analysis ABSTRACTKWDacquiredimmunodeficiencysyndrome/epidemiologycomorbiditycomparativestudycd4-positivet-lymphocytesfemalehumanhivinfections/KWDmortalityhivseropositivity/epidemiologyleukocytecountlifetablesmaleprobabilityriskfactorsscotland/epidemiologysexfactorssubstanceabuse,intravenous/epidemiologysurvivalanalysisabstract
921230
M92C5324

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .